1. Contractors
  2. The Institute for Cancer Research

The Institute for Cancer Research

Federal contractor · Research and Development in Biotechnology (except Nanobiotechnology)

The Institute for Cancer Research has 6 federal contracts of $100,000 or more active since October 2023, with $7.26M obligated, from 1 agency. 4 are still running, 4 ending within 18 months.

Contracts
6 since FY2024$7,255,309 obligated, contracts of $100,000 or more
Running now
4 contracts1 ended in the last 12 months
Biggest customer
National Institutes of Health$7.26M on 6 contracts
UEI
FF1XVJMDYVR1Unique entity ID in SAM.gov
Source
USAspending.govUpdated Nov 17, 2026, 7:02 PM UTC

Contracts by start year

Obligated so far on contracts active since October 2023, by the fiscal year each started. Fiscal years run Oct 1 to Sep 30.
Show as table
Fiscal yearContracts
FY2020$779,932
FY2022$4,237,145
FY2023$2,238,232

Running contracts

Soonest end first. An agency may compete the work again, extend the contract or move it to another vehicle.

End dates are the current period of performance; options not yet exercised can extend them. Each contract links to its record on USAspending.gov.

Who they work for

AgencyAmount
National Institutes of Health6 contracts$7,255,309

What they sell

IndustryAmount
Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 · 6 contracts$7,255,309

Where the work is

Place of workAmount
Pennsylvania6 contracts$7,255,309

Source: USAspending.gov, prime contracts of $100,000 or more with an action since October 1, 2023. Department of Defense contracts appear there about 90 days after award. Other contracts ending soon at National Institutes of Health: see the list.

Get new notices like The Institute for Cancer Research's work

New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.

Free. We use your email only for these alerts and never share it. Privacy